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Patients with insomnia complain of problems with sleep onset or sleep maintenance
or early morning awakenings, or a combination of these, despite adequate opportunity
and circumstances for sleep. In addition, to fulfill the diagnostic criteria for insomnia the
complaints need to be associated with negative daytime consequences. For chronic
insomnia, the symptoms are required to be present at least 3 days per week for a
duration of at least 3 months. Lastly, for insomnia to be defined as a disorder, the sleep
complaints and daytime symptoms should not be better explained by another sleep
disorder. This criterion represents a diagnostic challenge, since patients suffering from
other sleep disorders often complain of insomnia symptoms. For instance, insomnia
symptoms are common in e.g., obstructive sleep apnea and circadian rhythm sleep-
wake disorders. It may sometimes be difficult to disentangle whether the patient suffers
from insomnia disorder or whether the insomnia symptoms are purely due to another
sleep disorder. Furthermore, insomnia disorder may be comorbid with other sleep
disorders in some patients, e.g., comorbid insomnia and sleep apnea (COMISA). In
addition, insomnia disorder is often comorbid with psychological or somatic disorders
and diseases. Thus, a thorough assessment is necessary for correct diagnostics. For
chronic insomnia disorder, treatment-of-choice is cognitive behavioral therapy, and
such treatment is also effective when the insomnia disorder appears comorbid with
other diagnoses. Furthermore, studies suggest that insomnia is a heterogenic disorder
with many different phenotypes or subtypes. Different insomnia subtypes may respond
differently to treatment, but more research on this issue is warranted. Also, the role of
comorbidity on treatment outcome is understudied. This review is part of a Research
Topic on insomnia launched by Frontiers and focuses on diagnostic and treatment
challenges of the disorder. The review aims to stimulate to more research into the
bidirectional associations and interactions between insomnia disorder and other sleep,
psychological, and somatic disorders/diseases.
Keywords: chronic insomnia, cognitive behavioral therapy, sleep apnea, circadian rhythm sleep-wake disorder,
restless legs syndrome, parasomnia, hypersomnia, comorbidities
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INTRODUCTION
This review is part of a Research Topic on insomnia launched
by Frontiers and focuses on diagnostic and treatment challenges
of the disorder. Short sleep duration and insomnia are
associated with a multitude of health problems, such as anxiety,
depression, suicidal ideation, obesity, cardiovascular diseases,
cancer, dementia, and increased accident risk (Kecklund and
Axelsson, 2016; Riemann et al., 2017; Morin et al., 2020).
Furthermore, insomnia is prospectively associated with sick
leave and work disability (Sivertsen et al., 2009), and in fact, a
Norwegian study showed that insomnia complaints contributed
to work-related disability as much as, or even more than
depression (Overland et al., 2008).
Poor and short sleep can be caused by or associated with
a multitude of conditions. In order to guide clinicians in the
identification of specific disorders or diseases, the American
Academy of Sleep Medicine has developed the International
Classification of Sleep Disorders (ICSD), a diagnostic system used
within sleep medicine all around the world. In the third and
latest version of this classification, ICSD-3 (American Academy
of Sleep Medicine, 2014), sleep disorders are classified into
six main diagnostic categories: (1) insomnia; (2) sleep related
breathing disorders; (3) circadian rhythm sleep-wake disorders;
(4) sleep related movement disorders; (5) parasomnias; and (6)
central disorders of hypersomnolence (American Academy of
Sleep Medicine, 2014; Table 1). Further, each diagnostic category
entails several different separate diagnoses, totaling up to more
than 50 different sleep disorders. Often, patients may present
symptoms characteristic of several sleep disorders when seeking
help for their problem, that is, most sleep disorders usually
cause disturbances both during the night (e.g., poor and/or
interrupted sleep) and during the day (e.g., fatigue, sleepiness,
cognitive deficits, mood disturbances). However, even though
patients with different sleep disorders may present symptoms
or complaints which resemble each other, the treatment-of-
choice differs substantially between the different diagnostic
categories, as detailed below. Thus, a thorough diagnostic
assessment is a necessity in order to be able to best help patients
with sleep problems.
INSOMNIA DISORDER
Insomnia is considered the most common sleep disorder
(Riemann et al., 2017). Chronic insomnia disorder is defined
by subjective complaints with initiating or maintaining sleep,
despite adequate opportunity and circumstances for sleep.
Furthermore, the complaints need to be present at least 3 days per
week for a duration of at least 3 months (American Academy of
Sleep Medicine, 2014). In addition, the sleep complaints need to
be associated with negative daytime consequences (e.g., fatigue,
impairment in concentration or memory, mood disturbance,
lack of energy, dissatisfaction with sleep) to fulfill the diagnostic
criteria. Short-term (acute) insomnia has similar diagnostic
criteria, but the symptoms have a duration of less than 3 months
and no requirements are giving concerning number of days
TABLE 1 | Classification of sleep disorders and treatment-of-choice.
Diagnostic category including





Cognitive behavioral therapy for insomni
Sleep related breathing disorders
Obstructive sleep apnea
Central sleep apnea
Continuous positive airway pressure
Circadian rhythm sleep-wake disorders
Delayed sleep-wake phase disorder
Advanced sleep-wake phase disorder
Jet lag disorder
Bright light and/or exogenous melatonin
Sleep related movement disorders
Restless legs syndrome
Periodic limb movement disorder










per week with presence of symptoms. For both short-term and
chronic insomnia disorder, it is mandatory for the diagnosis that
the sleep disturbance and associated daytime symptoms are not
better explained by another sleep disorder (American Academy
of Sleep Medicine, 2014). It is important to note that there are
no objective criteria for the diagnosis of insomnia disorder. Thus,
polysomnography is not indicated. However, polysomnography
may be used to rule out other sleep disorders, e.g., obstructive
sleep apnea, and may be used for subtyping insomnia, e.g.,
insomnia with objective short sleep duration (Vgontzas et al.,
2013; American Academy of Sleep Medicine, 2014). The
prevalence of both acute and chronic insomnia symptoms in
the general population is high and considered to be on the
rise (Pallesen et al., 2014; Riemann et al., 2017). Furthermore,
insomnia disorder is often a persistent condition (Morin et al.,
2020). The prevalence depends on age, sex and socioeconomic
status, and several psychological and somatic disorders/diseases
occur comorbid with insomnia (Riemann et al., 2017). The strong
association between insomnia and depression has received much
research interest, and studies suggest that treatment targeting
insomnia symptoms will improve outcomes also for symptoms of
depression (Blom et al., 2015, 2017). A transdiagnostic approach
to treating sleep disturbance across different psychiatric disorders
was introduced by Harvey (2009) and such an approach has
gained popularity (Norton et al., 2013; Norton and Roberge, 2017;
Pearl and Norton, 2017). However, insomnia has traditionally not
received much attention in clinical practice. This is highlighted in
a study based on three independent and nationally representative
data-sets from mental health care centers in Norway, in which
the diagnosis of insomnia as a primary or comorbid diagnosis
was made only for 34 out of 42,507 patients (0.08%), even though
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about 40% of the patients experienced severe sleep disturbance
and 22% reported this to be one of their most prominent
problems (Kallestad et al., 2011).
The treatment-of-choice for chronic insomnia disorder is
cognitive behavioral therapy (CBTi), in which the behavioral
treatment components (the B in CBTi) sleep restriction and
stimulus control are shown to be the most effective components
(Morin et al., 1994; Brasure et al., 2016; Riemann et al., 2017).
Sleep restriction is a behavioral treatment method in which time
in bed is restricted to the actual time the patient sleeps, usually
based on estimates from sleep diaries. Patients with chronic
insomnia disorder typically spend 8–10 h in bed each night,
still often report only an average of 5 or less hours of sleep.
Initially, the patient is instructed to stay in bed only for this
estimated sleep duration (called the sleep window), e.g., from
02.00 to 07.00 h. Adjustments of the sleep window are made,
usually on a weekly basis, depending on the progress. If the
patient is asleep during most of the sleep window (e.g., sleep
efficiency is above 80–85%), time in bed is increased by 15–
30 min, until optimal sleep duration and daytime function are
reached. Stimulus control refers to a set of instructions with
the aim that the patient should break the often established link
between bed/bedroom and negative states (e.g., worry) and again
learn to associate bed/bedroom with relaxation and sleep in order
to reestablish a proper sleep-wake pattern. The instructions tell
the patient not to stay in bed, if sleep does not occur. This
means that the patient is instructed to get out of bed when
unable to sleep and to stay up until sleepiness resumes. The
bedroom should be used only for sleep (and sex), and not for e.g.,
work, TV watching or use of electronic media. Furthermore, the
patient is instructed to set a fixed rise time in the morning. In
addition to behavioral treatment components, CBTi also includes
cognitive strategies (the C in CBTi) to identify, challenge and
change dysfunctional beliefs, attitudes and misconceptions about
sleep and insomnia (Riemann et al., 2017). Cognitive factors have
been identified as major factors driving insomnia (Harvey, 2002).
Many patients with insomnia focus on their complaints and its
consequences. Unfortunately, “trying to sleep” is not an effective
method and tends to only lead to more insomnia. It has been
argued that the attentional system in patients with insomnia may
be abnormally sensitive to sleep-related information (Harris et al.,
2015). This leads to increased rumination and intention toward
sleeping (Harvey, 2002; Espie et al., 2006). Other CBT-strategies
such as problem solving, for instance on how to deal with pre-
sleep cognitions and cope with stress, can also be included. Other
treatment components sometimes included in CBTi comprise
sleep hygiene, which is basic advice (e.g., not drink coffee too
late) on how to promote sleep, and various relaxation techniques
to counteract physiological, emotional and cognitive activation.
Unfortunately, CBTi is often not available for patients with
chronic insomnia, and most patients still receive treatment
in terms of medications and/or general sleep hygiene advice
(Cheung et al., 2019). Thus, easily implementable therapies in
clinical practice are clearly needed. CBTi delivered through the
Internet (Ritterband et al., 2009; Espie et al., 2012) or through
self-help books (Bjorvatn et al., 2011; Jernelov et al., 2012) show
promising results. Before returning to insomnia, we will present
the other main sleep disorder categories briefly.
SLEEP RELATED BREATHING
DISORDERS
The diagnostic group sleep related breathing disorders consist of
many different disorders, in which obstructive sleep apnea (OSA)
is the most common and well-known (American Academy of
Sleep Medicine, 2014). The sleep related breathing disorders are
characterized by abnormal respiration during sleep with frequent
apneas and/or hypopneas. Patients with OSA typically complain
of poor and non-restorative sleep at night and fatigue during
daytime. Thus, symptoms may appear similar to insomnia,
however, the assessment and recommended treatment differ
greatly. Insomnia disorder is a purely subjective diagnosis, based
on a clinical interview with the patient, and with no objective
criteria. On the other hand, OSA requires objective findings
on polysomnographic or polygraphic recordings (American
Academy of Sleep Medicine, 2014). In fact, if the apnea-hypopnea
index (AHI) is 15 or higher per hour on objective recordings, the
diagnostic criteria for OSA are fulfilled even if the patient has no
symptoms. If AHI is 5–15 per hour, the diagnostic criteria require
some sort of symptoms or signs (e.g., snoring, breathing pauses
during sleep, hypertension). The prevalence of OSA is especially
high among males, and increases with age (Gabbay and Lavie,
2012) and with increasing weight (Romero-Corral et al., 2010).
Treatment-of-choice for moderate to severe OSA is continuous
positive airway pressure (CPAP) (Epstein et al., 2009).
CIRCADIAN RHYTHM SLEEP-WAKE
DISORDERS
Circadian rhythm sleep-wake disorders are characterized by
a persistent or recurrent pattern of sleep disturbance due
to alterations of the circadian timing system (e.g., delayed
sleep-wake phase disorder) or a misalignment between the
individual endogenous circadian rhythm and exogenous factors
influencing the timing, duration and quality of sleep (e.g.,
jet lag disorder) (Bjorvatn and Pallesen, 2009; American
Academy of Sleep Medicine, 2014). Circadian rhythm sleep-
wake disorders typically lead to insomnia symptoms and
daytime sleepiness and fatigue. Delayed sleep-wake phase
disorder is characterized by a significant delay of the major
sleep episode evidenced by inability to fall asleep and wake
up at a desired or required clock time (American Academy
of Sleep Medicine, 2014). However, in contrast to insomnia
disorder, patients with delayed sleep-wake phase disorder
exhibit normal sleep quality and quantity when allowed to
follow their ad libitum schedule. Thus, whereas patients with
insomnia disorder have problems with sleep independent of
time, patients with a circadian rhythm sleep-wake disorder
have no problems with sleep per se, but they have difficulties
with sleeping at the appropriate or desired time of day. In
adolescence, delayed sleep-wake phase disorder may be even
more prevalent than insomnia disorder (American Academy of
Sleep Medicine, 2014). Treatment-of-choice is different from
insomnia and consists of scheduled (timed in relation to
the patient’s circadian rhythm) administration of bright light
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and/or exogenous melatonin (Wilhelmsen-Langeland et al., 2013;
Saxvig et al., 2014).
SLEEP RELATED MOVEMENT
DISORDERS
Sleep related movement disorders are characterized by repetitive
movements that disturb sleep (American Academy of Sleep
Medicine, 2014). Of the sleep related movement disorders,
restless legs syndrome/Willis-Ekbom disease is the most
well-known. This disorder is characterized by an urge to
move the legs due to unpleasant sensations. Symptoms begin
or worsen during inactivity/rest and are partially or totally
relieved by movement. Typically the symptoms present
only in the evening or at night (American Academy of
Sleep Medicine, 2014). Notably, the diagnosis of restless legs
syndrome only requires subjective reports from the patient,
hence no objective recordings are required. Patients with
severe restless legs syndrome often complain of sleep onset
problems, due to the unpleasant sensations, but they also
experience poor sleep quality and daytime fatigue/sleepiness.
This may result from the fact that restless legs syndrome
is closely associated with periodic limb movements during
sleep (American Academy of Sleep Medicine, 2014). Thus,
symptoms associated with restless legs syndrome may resemble
symptoms associated with insomnia disorder. As for insomnia
disorder, restless legs syndrome is more common in females
compared to males, and the prevalence increases with age
(Hening et al., 2007). The treatment-of-choice for severe
restless legs syndrome and periodic limb movements during
sleep is medications, in which dopamine agonists or alpha2-
delta ligands are most commonly used (Liu et al., 2016;
Garcia-Borreguero and Cano-Pumarega, 2017).
PARASOMNIAS
Parasomnias are a group of sleep disorders pertaining to
undesirable physical events or experiences that occur during
entry into sleep, within sleep or during arousal from sleep
(American Academy of Sleep Medicine, 2014). These disorders
are divided into those arising from deep sleep [non-rapid-eye
movement (NREM) sleep], rapid-eye movement (REM) sleep,
and those not arising from any specific sleep stage. Well-
known NREM-parasomnias are sleep walking (somnambulism),
sleep terrors and sleep-related eating disorder. Nightmare
disorder and REM-sleep behavioral disorder are examples of
REM-parasomnias (Bjorvatn et al., 2010; American Academy
of Sleep Medicine, 2014). Overall, parasomnias often disturb
sleep quality and quantity, and lead to daytime fatigue and
sleepiness. A majority of the parasomnias are more prevalent in
young versus old age, and also in females compared to males
and in patients with mental health problems (Bjorvatn et al.,
2010; Li et al., 2010). Treatment-of-choice varies depending
on severity, but sleep hygiene advice may often be sufficient
(Ntafouli et al., 2020).
CENTRAL DISORDERS OF
HYPERSOMNOLENCE
Central disorders of hypersomnolence (hypersomnias) are
characterized by excessive daytime sleepiness. Most of these
disorders are rare and include severe neurological conditions,
such as narcolepsy (Heier et al., 2009; American Academy of
Sleep Medicine, 2014). Although the main complaint is excessive
daytime sleepiness, patients with narcolepsy may also complain
of poor sleep quality and sleep fragmentation. Thus, insomnia
symptoms may be present among patients also in this diagnostic
category (American Academy of Sleep Medicine, 2014; Thorpy
and Bogan, 2020). The assessment and diagnostic criteria of
central disorders of hypersomnolence (e.g., narcolepsy) require
objective sleep recordings (polysomnography and multiple sleep
latency test) or measurement of hypocretin levels in the
cerebrospinal fluid (American Academy of Sleep Medicine,
2014). Treatment-of-choice is wake-promoting medications
(Thorpy and Bogan, 2020).
DISCUSSION
Insomnia symptoms may be present in all the different sleep
disorders, as highlighted above. Importantly, the diagnostic
criteria require that the diagnosis of insomnia disorder should
only be used when the symptoms may not be better explained
by another sleep disorder. Sometimes it is difficult to disentangle
whether the patient suffers from insomnia disorder or whether
the symptoms are an indication of another sleep disorder.
Furthermore, some patients may suffer from both insomnia
disorder and another sleep disorder with insomnia symptoms.
For instance, it is not uncommon that patients with OSA also
have insomnia disorder, that is, comorbid insomnia and OSA
(so-called COMISA) (Sweetman et al., 2019a). Hence, thorough
clinical assessment and proper diagnostic evaluation are of great
importance, as the final diagnosis reached has serious treatment
implications. CBTi is very effective in patients with insomnia
disorder but may not be recommended if the insomnia symptoms
are purely due to another sleep disorder. In line with this, and
due to limited research on the use of CBTi with these patient
groups, CBTi and especially the behavioral treatment component
sleep restriction, may not be advised in patients with e.g., OSA or
delayed sleep-wake phase disorder, as it may cause adverse effects,
i.e., increased daytime sleepiness. Also, if the patient suffers
from OSA, and it seems likely that the apneas and hypopneas
are causing the insomnia symptoms, treatment with CPAP will
reduce these symptoms (Bjornsdottir et al., 2013; Mysliwiec
et al., 2020). Similarly, if the insomnia symptoms are due to
e.g., delayed sleep-wake phase disorder, bright light or exogenous
melatonin administration will effectively reduce the insomnia
symptoms (Saxvig et al., 2014).
However, as mentioned, sometimes it is difficult to disentangle
between insomnia disorder and insomnia symptoms due to
another sleep disorder, or whether the patient in fact suffers
from comorbidity, that is, both insomnia disorder and another
sleep disorder. In line with this, several recent studies show
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that treatment with CBTi reduces the insomnia complaints
in patients with COMISA (comorbid insomnia and OSA)
(Sweetman et al., 2017, 2020; Ong et al., 2020) and may also
improve CPAP adherence (Sweetman et al., 2019b). Thus, in
comorbid conditions, the recommended treatment should be to
focus on both sleep disorders (Ong et al., 2020).
To differentiate between insomnia disorder and insomnia
symptoms has also important implications when studying
prevalence. Several papers indicate that chronic insomnia is the
most common sleep disorder (Riemann et al., 2017). However,
even though well-validated instruments such as the Insomnia
Severity Index (Bastien et al., 2001) and the Bergen Insomnia
Scale (Pallesen et al., 2008) are being used, a definite distinction
between insomnia disorder and insomnia symptoms due to
other sleep disorders (e.g., OSA or a circadian rhythm sleep-
wake disorder), is not easy to make in questionnaire-based
epidemiological studies. For instance, in a questionnaire study
(using the Bergen Insomnia Scale) among patients visiting their
general practitioner about 50% of the participants fulfilled the
criteria for chronic insomnia (Bjorvatn et al., 2017). However,
that study (Bjorvatn et al., 2017) and several other studies (Morin
et al., 2006; Hysing et al., 2013; Mallon et al., 2014; Pallesen
et al., 2014; Sivertsen et al., 2014) which report prevalences of
chronic insomnia are often not able to exclude the possibility
that the insomnia symptoms may be better explained by other
sleep disorders, such as OSA. Thus, while epidemiological studies
indicate a very high prevalence of insomnia disorder, these
prevalence numbers do not necessarily indicate how many should
be treated with CBTi, as some of these patients with chronic
insomnia symptoms may suffer from sleep disorders other than
insomnia disorder. We therefore recommend caution when
interpreting prevalence of sleep disorders from epidemiological
studies, as a definite diagnosis of insomnia disorder should be
based on a clinical interview, preferably by a clinician with
expertise in sleep medicine. Even in such cases misdiagnosis may
occur, and when patients compliant with CBTi do not experience
improvement, referral to objective sleep recordings may be
warranted. At the same time, under-diagnosing of insomnia,
and the use of treatments not following guidelines is a problem,
resulting in many patients not receiving adequate treatment for
their insomnia (Baglioni et al., 2020).
Traditionally, sleep problems have been regarded as
consequences of other underlying conditions such as mental
health difficulties or somatic diseases. However, this perspective
has changed significantly during the last decade, and recent
diagnostic classification systems [e.g., ICSD-3 (American
Academy of Sleep Medicine, 2014), DSM-5 (American
Psychiatric Association, 2013)] recommend focusing on
sleep problems as independent conditions (Riemann et al.,
2017). It is now recognized that sleep disorders can no longer
be considered only as symptoms, but also as major causative
factors of a wide array of problems (Harvey, 2001). In keeping
with this, pain has been pointed to as a sleep disturbing factor,
but evidence also suggests that poor sleep exacerbates pain
(Finan et al., 2013). Sleep disturbance is further recognized as a
strong feature of psychopathology as it has been associated with
a wide array of psychiatric disorders, such as depression, bipolar
disorder, psychotic disorders, anxiety disorders, ADHD, and
eating disorders (Sateia, 2009). Although insomnia symptoms are
conceivably a part of the diagnostic criteria of several psychiatric
disorders (Costantini et al., 2020), it is fairly well demonstrated
that insomnia constitutes a risk factor for the development
of depression and anxiety in particular (Lovato and Gradisar,
2014; Sivertsen et al., 2014). Furthermore, it is often difficult to
conclude whether insomnia symptoms are due to depression
or causing depressed mood. Therefore, treatment of both
insomnia and depression is recommended when both disorders
are present, irrespective of which symptoms came first. Several
somatic illnesses, such as diabetes, asthma, epilepsy, rheumatic
disorders (Lazaratou et al., 2012), are associated with insomnia.
Insomnia may be a result of discomfort caused by the medical
condition or it can be caused by the same mechanism as the
somatic disorder. On the other hand, insomnia may aggravate
somatic disorders, and vicious cycles in which sleep problems
and somatic disorders exacerbate each other reciprocally have
been described (Lazaratou et al., 2012). Furthermore, sleep can
also be impaired as a consequence of treatment regimens related
to both psychiatric and somatic disorders. For instance, several
antidepressants may disturb sleep (Hauser et al., 2013). For many
disorders and conditions where comorbidity with insomnia is
present, it has been shown that CBTi can be used to improve
sleep (Geiger-Brown et al., 2015), and sometimes also to improve
the symptoms of the other condition (Belleville et al., 2011; Blom
et al., 2015; Wu et al., 2015).
Several recent studies suggest that insomnia is a heterogenic
disorder with different phenotypes or subtypes. For instance,
insomnia with objective short sleep duration may be a more
severe subtype than other subtypes (Vgontzas et al., 2013).
A recent study suggested to divide insomnia into subtypes
based on non-sleep characteristics such as life history, mood
perceptions, and personality (Blanken et al., 2019). Further,
insomnia may be divided into subtypes based on assumed
etiology (e.g., psychophysiological, paradoxical, inadequate sleep
hygiene), as suggested in the previous version of the International
Classification of Sleep Disorders (American Academy of Sleep
Medicine, 2005). Insomnia subtypes may also be based on
consistency (persistent, remission, relapse) (Wu et al., 2014).
In clinical practice, the most commonly used subdivision is
related to when in the main sleep period (at sleep onset,
during the sleep period, or in the morning) the insomnia
symptoms occur (Yokoyama et al., 2010; Bjoroy et al., 2020).
In a recent population-based study with more than 60,000
participants, it was shown that the symptoms of anxiety and
depression, and hypnotic use, were higher among participants
with insomnia consisting of a combination of sleep onset,
sleep maintenance, and early morning awakening problems as
compared to participants with other insomnia subtypes (e.g.,
insomnia with pure sleep onset or sleep maintenance problems)
(Bjoroy et al., 2020).
In clinical practice, different subtypes may respond differently
to treatment (Riemann et al., 2017). For instance, CBTi may
be more effective in patients with sleep onset problems than
among patients with pure early morning awakening; hence more
research on different insomnia subtypes is warranted. The role
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of comorbid conditions, both psychological and somatic, on
treatment outcomes is also understudied. One goal of this review
is therefore to inspire research into the bidirectional associations
and interactions between insomnia and other psychological and
somatic conditions.
An important point to make is that subtyping insomnia
symptoms may be helpful in the diagnostic assessment. For
instance, sleep onset problems per se are not typical in patients
with OSA. Patients with OSA more commonly complain of
nocturnal awakenings and non-restorative sleep (Bjornsdottir
et al., 2013). Thus, if a patient with OSA also has severe sleep onset
problems, the presence of a comorbid insomnia disorder is more
likely than if the patient mainly complains of sleep maintenance
problems. Similarly, if a patient has severe sleep onset problems
but no problems maintaining sleep, and is able to sleep for more
than 7–8 h, a delayed sleep-wake phase disorder is more likely
than an insomnia disorder (Bjorvatn and Pallesen, 2009).
Although CBTi may not, based on current (lack of) evidence,
be indicated in cases where insomnia symptoms clearly are
secondary to another condition, clinicians should still be
aware that insomnia symptoms may prevail (e.g., due to
irrational compensatory behavior and negative conditioning)
after successful treatment of the main disorder. In cases where
the clinician prioritizes treatment of the main disorder expecting
this also to provide an indirect effect on sleep, he or she should
keep track of how the patient is sleeping. If sleep problems persist
following successful treatment of the main disorder, treatment
focus should then be on the insomnia symptoms.
In conclusion, patients often present similar symptoms
irrespective of sleep disorder, that is, they complain of poor sleep
and impaired daytime function. However, as treatment-of-choice
varies substantially between the different sleep disorders, it is of
great importance that clinicians are able to separate insomnia
disorder from other sleep disorders. A thorough diagnostic
assessment is thus crucial. At the same time, co-morbidity with
other disorders and conditions is high, insomnia is often not
recognized in healthcare, and CBTi, which is the recommended
treatment, is often not provided. Insomnia symptoms may
represent a separate disorder, be symptoms of another sleep
disorder, or represent a comorbid disorder. We recommend
treatment dependent on the diagnosis being made, that is, if
insomnia disorder is present, either as the only diagnosis or as
a comorbid disorder, treatment with CBTi is recommended.
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